ADMA Biologics Under Investigation
Leading securities law firm Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) concerning possible violations of federal securities laws. This comes after the unexpected resignation of its independent auditor, CohnReznick LLP, which has raised concerns among investors.
The Resignation of the Auditor
The recent news has caught many off guard, especially since the auditor's resignation, announced on October 9, 2024, has led to a significant decline in ADMA Biologics's stock price. The following day, the stock fell more than 20%, sparking alarm among shareholders.
What Led to the Stock Drop?
The biopharmaceutical company ADMA Biologics focuses on the manufacture and development of specialty biologics aimed at treating patients with compromised immune systems. The abrupt departure of CohnReznick LLP has raised serious questions about the company’s internal controls and financial reporting, which likely contributed to the drop in stock value.
Potential Legal Options for Investors
For those who have invested in ADMA Biologics, the firm is urging shareholders to seek additional information regarding their legal rights. Bleichmar Fonti & Auld LLP states that investors may have options available and should consider reaching out to them. The firm represents clients on a contingency basis, meaning there are no upfront costs involved, and shareholders are not liable for court or litigation expenses.
How to Get Involved
If you own shares in ADMA Biologics and wish to understand your rights better, you’re encouraged to submit your information through the law firm's provided channels. This step may help in joining potential claims related to the securities fraud investigation.
About Bleichmar Fonti & Auld LLP
Bleichmar Fonti & Auld LLP is a prestigious international law firm known for its strong representation of plaintiffs in securities class actions and shareholder litigation. The firm was recognized among the top plaintiff law firms in 2023, showing a history of successful recoveries for clients in various high-profile cases.
Track Record of Success
The firm's recent accomplishments include recovering substantial sums for shareholders from companies like Tesla, Inc. and Teva Pharmaceutical Industries Ltd., establishing its credibility in the field of securities litigation.
Conclusion
As the investigation into ADMA Biologics progresses, investors should remain alert and informed about their rights. The actions taken by auditors and the responses from the company can significantly influence stock performance and shareholder value.
Frequently Asked Questions
What is the reason for the audit resignation?
The resignation of CohnReznick LLP has raised concerns about ADMA Biologics's financial controls, which negatively affected its stock price.
How can affected investors get help?
Investors can contact Bleichmar Fonti & Auld LLP to evaluate their legal options regarding the recent developments.
Is there a cost involved for investors seeking legal aid?
No, Bleichmar Fonti & Auld LLP operates on a contingency fee basis, meaning there are no upfront costs to investors.
What could happen next in this investigation?
The investigation may lead to class action lawsuits if enough evidence is gathered on potential wrongdoing by the company.
Should I sell my shares in ADMA Biologics?
Investors should carefully assess their positions and consider professional legal advice before making any decisions regarding their shares.
